Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354523 · ClinicalTrials.gov registry record · Phase 1
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00354523: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00354523 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00354523, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors. To determine the overall tumor response rate to imatinib mesylate in combination with capecitabine and dacarbazine as first line and second line therapy in advanced metastatic medullary thyroid carcinoma. To determine the tolerability (toxicity) of this regimen. Secondary objectives: To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination.
Interventions
- DRUG Capecitabine (Xeloda)
- DRUG DTIC-Dome (Dacarbazine)
- DRUG Gleevec (Imatinib Mesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354523
The ClinicalTrials.gov registry entry for NCT00354523 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine (Xeloda) is the first listed.
NCT00354523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354523 about?
NCT00354523 is a clinical study titled "Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma". Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors. To determine the overall tumor response rate to imatinib mesylate in combination with capecitabine and dacarbazine ...
What is the current status of trial NCT00354523?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2004-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00354523?
The interventions under investigation include: Capecitabine (Xeloda) (DRUG), DTIC-Dome (Dacarbazine) (DRUG), Gleevec (Imatinib Mesylate) (DRUG).
Who is sponsoring clinical trial NCT00354523?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.